UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

SCHEDULE 13G

 

Under the Securities Exchange Act of 1934

(Amendment No. 1)*

 

OnKure Therapeutics, Inc.
(Name of Issuer)
 
Common Stock, $0.0001 par value
(Title of Class of Securities)

 

  68277Q105  
  (CUSIP Number)  
 
October 4, 2024
(Date of Event Which Requires Filing of This Statement)

 

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

 

  x Rule 13d-1(b)
     
  ¨ Rule 13d-1(c)
     
  ¨ Rule 13d-1(d)

 

 

*The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

 

The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

 

 

 

 Page 1 of 8 
 

 

CUSIP No.  68277Q105
1

NAMES OF REPORTING PERSONS

I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

 

Octagon Capital Advisors LP

2

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions)

 

 

(a)¨

(b)¨

3

SEC® USE ONLY

 

 

4

CITIZENSHIP OR PLACE OF ORGANIZATION

 

Delaware

NUMBER OF

SHARES

BENEFICIALLY

OWNED BY

EACH REPORTING

PERSON WITH:

 5

SOLE VOTING POWER

 

0

6

SHARED VOTING POWER

 

225,000

7

SOLE DISPOSITIVE POWER

 

0

8

SHARED DISPOSITIVE POWER

 

225,000

9

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

 

225,000

10

CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (see instructions)

 

¨

11

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

 

1.8%

12

TYPE OF REPORTING PERSON (see instructions)

 

IA, PN

 

 Page 2 of 8 
 

 

CUSIP No.  68277Q105
1

NAMES OF REPORTING PERSONS

I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

 

Octagon Investments Master Fund LP

2

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions)

 

 

(a)¨

(b)¨

3

SEC® USE ONLY

 

 

4

CITIZENSHIP OR PLACE OF ORGANIZATION

 

Cayman Islands

NUMBER OF

SHARES

BENEFICIALLY

OWNED BY

EACH REPORTING

PERSON WITH:

 5

SOLE VOTING POWER

 

0

6

SHARED VOTING POWER

 

225,000

7

SOLE DISPOSITIVE POWER

 

0

8

SHARED DISPOSITIVE POWER

 

225,000

9

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

 

225,000

10

CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (see instructions)

 

¨

11

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

 

1.8%

12

TYPE OF REPORTING PERSON (see instructions)

 

OO, PN

 

 Page 3 of 8 
 

 

CUSIP No.  68277Q105
1

NAMES OF REPORTING PERSONS

I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

 

Ting Jia

2

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions)

 

 

(a)¨

(b)¨

3

SEC® USE ONLY

 

 

4

CITIZENSHIP OR PLACE OF ORGANIZATION

 

China

NUMBER OF

SHARES

BENEFICIALLY

OWNED BY

EACH REPORTING

PERSON WITH:

 5

SOLE VOTING POWER

 

0

6

SHARED VOTING POWER

 

225,000

7

SOLE DISPOSITIVE POWER

 

0

8

SHARED DISPOSITIVE POWER

 

225,000

9

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

 

225,000

10

CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (see instructions)

 

¨

11

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

 

1.8%

12

TYPE OF REPORTING PERSON (see instructions)

 

HC, IN

 

 Page 4 of 8 
 

 

Item 1(a). Name of Issuer:
   
   OnKure Therapeutics, Inc.
   
Item 1(b). Address of Issuer’s Principal Executive Offices:
   
  

6707 Winchester Circle, Suite 400, Boulder, CO 80301

   
Item 2(a). Name of Person Filing:
   
  

This statement is being jointly filed by:

 

Octagon Capital Advisors LP (“Octagon”)

Octagon Investments Master Fund LP (“Master Fund”)

Ting Jia, as the principal beneficial owner of Octagon (“Mr. Jia”)

 

Each of the foregoing is referred to as a “Reporting Person” and collectively as the “Reporting Persons.”

 

Octagon serves as the investment manager of the Master Fund. Mr. Jia is the managing member of Octagon. By virtue of these relationships each of Octagon and Mr. Jia may be deemed to beneficially own the Issuer’s Common Shares directly owned by the Master Fund.

 

   
Item 2(b). Address of Principal Business Office or, if none, Residence:
     
   The address of the business office of each of the Reporting Persons is 654 Madison Avenue, 21st Floor, New York, NY 10065
   
Item 2(c). Citizenship:
   
   Octagon is a Delaware limited partnership. The Master Fund is an exempted limited partnership established in the Cayman Islands. Mr. Jia is a Chinese citizen.
   
Item 2(d). Title of Class of Securities:
   
   Common Stock, $0.0001 par value (the “Common Shares”)
   
Item 2(e). CUSIP Number:  68277Q105

 

 Page 5 of 8 
 

 

Item 3. If this Statement is filed pursuant to 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
  (a) ¨ Broker or dealer registered under Section 15 of the Act;
  (b) ¨ Bank as defined in Section 3(a)(6) of the Act;
  (c) ¨ Insurance company as defined in Section 3(a)(19) of the Act;
  (d) ¨ Investment company registered under Section 8 of the Investment Company Act of 1940;
  (e) x An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E);
  (f) ¨ An employee benefit plan or endowment fund in accordance with Rule 13d-1(b)(1)(ii)(F);
  (g) x A parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G);
  (h) ¨ A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
  (i) ¨ A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940;
  (j) ¨ A non-U.S. institution in accordance with Rule 240.13d-1(b)(1)(ii)(J);
  (k) ¨ Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with Rule 240.13d-1(b)(1)(ii)(J), please specify the type of institution:      

 

Item 4. Ownership.
  Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.
   (a) Amount Beneficially Owned: 225,000
   (b)

Percent of Class:

 1.8%
      The percentage reported on this Schedule 13G is calculated based upon a statement in the Issuer’s Current Report on Form 8-K filed on October 8, 2024 that there would be 12,652,811 Class A Common Shares outstanding immediately after the closing of the Issuer’s merger with Reneo Pharmaceuticals, Inc. and concurrent private placement.  
   (c)

Number of shares as to which such person has:

      (i) sole power to vote or to direct the vote: 0
      (ii) shared power to vote or to direct the vote: 225,000
      (iii) sole power to dispose or to direct the disposition of: 0
      (iv) shared power to dispose or to direct the disposition of: 225,000

 

 Page 6 of 8 
 

 

Item 5. Ownership of Five Percent or Less of a Class.
   
   If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following x.
   
 Item 6. Ownership of More than Five Percent on Behalf of Another Person.
   
   Octagon is the investment advisor to the Master Fund and other accounts. Mr. Jia is the control person of Octagon. The Master Fund holds the Common Shares for the benefit of its investors. The Master Fund and Octagon, for the benefit of its investors, have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the Common Shares.
   
Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company.
   
   Not applicable.
   
Item 8. Identification and Classification of Members of the Group.
   
   Not applicable.
   
Item 9. Notice of Dissolution of Group.
   
   Not applicable.
   
Item 10. Certification.
   
   By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

 

 Page 7 of 8 
 

 

SIGNATURE

 

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

 

Date: October 28, 2024 OCTAGON CAPITAL ADVISORS LP
   
  /s/ Ting Jia  
  Name: Ting Jia  
  Title: Managing Member  

 

 

 

  OCTAGON INVESTMENTS MASTER FUND LP
  By: Octagon Investments GP, LLC, its general partner

 

  /s/ Ting Jia  
  Name: Ting Jia  
  Title: Managing Member  
 

 

 

 

TING JIA

 

/s/ Ting Jia

 
  Name: Ting Jia  

 

 

Page 8 of 8

 

 

 

Reneo Pharmaceuticals (NASDAQ:RPHM)
Graphique Historique de l'Action
De Nov 2024 à Déc 2024 Plus de graphiques de la Bourse Reneo Pharmaceuticals
Reneo Pharmaceuticals (NASDAQ:RPHM)
Graphique Historique de l'Action
De Déc 2023 à Déc 2024 Plus de graphiques de la Bourse Reneo Pharmaceuticals